A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Trial Profile

A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Suspended
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Tenatumomab I-131 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors sigma-tau SpA
  • Most Recent Events

    • 04 Nov 2016 Planned End Date changed from 1 Jun 2017 to 1 Feb 2018.
    • 04 Nov 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 04 Nov 2016 Status changed from active, no longer recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top